Lumida
/GOCO
⌘K
Gohealth Inc

Gohealth Inc

GOCO
$0.31USD+5.14%+0.01 today

MARKET CAP

9.9M

P/E (TTM)

FWD P/E

DAY RANGE

$0 – $0

52W RANGE

$0
$7

AI Summary

Stalk
Sell NowHigh

GOCO remains in a Stage 4 decline with persistent lower highs and lower lows under declining EMAs. Relief rallies into the 9/20/50EMA and 50DMA quickly reject, and volume clusters on down moves confirm supply dominance. Short-term trend is down, with no exhaustion visible, making selling now into any bounce the optimal execution posture.

  • Q4 ’24 revenue $389 M (+41% YoY) driven by operational efficiency
  • CAC $501/submission (–27% YoY) reflects improved marketing strategies
  • Q3 ’25 revenue $95 M down as focus shifted to quality over volume
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$1.1B$631.7M$734.7M$798.9M$361.8M
YoY %+21.1%-40.5%+16.3%+8.7%-54.7%
P / Sales0.4x0.1x0.2x0.2x0.1x
EV / Sales1.4x1.8x1.5x1.4x2.7x
Gross Profit, Adj.$823.1M$444.0M$575.7M$668.3M$265.7M
YoY %+21.4%-46.1%+29.7%+16.1%-60.2%
Margin %77.5%70.3%78.4%83.7%73.4%
EV / Gross Profit1.8x2.6x1.9x1.7x3.7x
EBITDA, Adj.$10.7M$-174.1M$36.8M$98.8M$-72.8M
YoY %-68.5%-1726.2%+121.1%+168.9%-173.7%
Margin %1.0%-27.6%5.0%12.4%-20.1%
EV / EBITDA139.5x-6.5x29.3x11.4x-13.6x
EBIT$-489.4M$-318.7M$-81.7M$-7.0M$-412.9M
YoY %-658.3%+34.9%+74.4%+91.4%-5759.2%
Margin %-46.1%-50.4%-11.1%-0.9%-114.1%
EV / EBIT-3.1x-3.6x-13.2x-159.3x-2.4x
Net Income$-189.4M$-149.6M$-66.8M$-6.6M$-261.1M
YoY %-907.1%+21.0%+55.3%+90.1%-3861.9%
Net Margin-17.8%-23.7%-9.1%-0.8%-72.1%
EPS (GAAP)-$26.80-$17.72-$7.19-$0.66-$20.17
YoY %-700.0%+33.9%+59.4%+90.8%-2956.1%